RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
1-Year Return
12.81%
This Quarter Return
+7.19%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$811M
AUM Growth
+$71.2M
(+9.6%)
Cap. Flow
+$37.6M
Cap. Flow
% of AUM
4.63%
Top 10 Holdings %
Top 10 Hldgs %
28.89%
Holding
102
New
7
Increased
37
Reduced
34
Closed
10
Top Buys
| 1 |
Becton Dickinson
BDX
|
$16.3M |
| 2 |
CVS Health
CVS
|
$15.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
$13.9M |
| 4 |
CELG
Celgene Corp
CELG
|
$12M |
| 5 |
Cigna
CI
|
$10.9M |
Top Sells
| 1 |
Nektar Therapeutics
NKTR
|
$15.5M |
| 2 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$11.5M |
| 3 |
Esperion Therapeutics
ESPR
|
$10.3M |
| 4 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.14M |
| 5 |
Cencora
COR
|
$6.03M |
Sector Composition
| 1 | Healthcare | 94.68% |
| 2 | Technology | 0.23% |
| 3 | Energy | 0.22% |
| 4 | Financials | 0.18% |
| 5 | Consumer Discretionary | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Halliburton
HAL
$19.2B
| $688K | 0.08% |
14,659
+3,515
| +32% | +$165K |
|
77
Exxon Mobil
XOM
$479B
| $636K | 0.08% |
8,526
+2,830
| +50% | +$211K |
|
78
JPMorgan Chase
JPM
$835B
| $593K | 0.07% |
5,391
+873
| +19% | +$96K |
|
79
Janus Henderson
JHG
$7.03B
| $591K | 0.07% |
17,859
+5,953
| +50% | +$197K |
|
80
IBM
IBM
$230B
| $579K | 0.07% |
3,947
+2,100
| +114% | +$308K |
|
81
Microsoft
MSFT
$3.78T
| $499K | 0.06% |
5,465
+672
| +14% | +$61.4K |
|
82
Chevron
CVX
$318B
| $473K | 0.06% |
+4,148
| New | +$473K |
|
83
Ford
F
$46.5B
| $472K | 0.06% |
42,606
+14,202
| +50% | +$157K |
|
84
AB InBev
BUD
$116B
| $463K | 0.06% |
4,209
+1,403
| +50% | +$154K |
|
85
Walt Disney
DIS
$214B
| $463K | 0.06% |
+4,613
| New | +$463K |
|
86
Qualcomm
QCOM
$172B
| $446K | 0.06% |
8,052
+2,684
| +50% | +$149K |
|
87
STAAR Surgical
STAA
$1.38B
| $365K | 0.05% |
24,658
-51,598
| -68% | -$764K |
|
88
Gen Digital
GEN
$18.2B
| $363K | 0.04% |
14,039
+4,680
| +50% | +$121K |
|
|
RGLS
89
DELISTED
Regulus Therapeutics
RGLS
| $354K | 0.04% |
4,107
| – | – |
|
90
Pfizer
PFE
$140B
| $311K | 0.04% |
9,227
-1,758
| -16% | -$59.3K |
|
91
Wells Fargo
WFC
$262B
| $307K | 0.04% |
5,858
-1,777
| -23% | -$93.1K |
|
|
RARX
92
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $208K | 0.03% |
39,115
-69,336
| -64% | -$369K |
|
93
Dynavax Technologies
DVAX
$1.17B
| – | – |
-242,812
| Closed | -$4.54M |
|
94
DexCom
DXCM
$31.7B
| – | – |
-282,500
| Closed | -$4.05M |
|
95
HCA Healthcare
HCA
$96.3B
| – | – |
-58,886
| Closed | -$5.17M |
|
96
Puma Biotechnology
PBYI
$257M
| – | – |
-50,000
| Closed | -$4.94M |
|
97
Ultragenyx Pharmaceutical
RARE
$3.01B
| – | – |
-95,000
| Closed | -$4.41M |
|
98
Universal Health Services
UHS
$11.8B
| – | – |
-52,433
| Closed | -$5.94M |
|
|
NVRO
99
DELISTED
NEVRO CORP.
NVRO
| – | – |
-15,145
| Closed | -$1.05M |
|
|
ICPT
100
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-38,500
| Closed | -$2.25M |
|